Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics (CRSP)
NASDAQ:CRSP
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 35.00M | $ 370.00M | $ 436.00K | $ 913.08M | $ 719.00K |
| Gross Profit | $ -75.25M | $ 239.75M | $ -109.81M | $ 811.90M | $ -268.69M |
| Operating Income | $ -466.57M | $ -222.54M | $ -673.16M | $ 373.53M | $ -354.44M |
| EBITDA | $ -447.31M | $ -202.70M | $ -648.99M | $ 391.48M | $ -345.25M |
| Net Income | $ -366.25M | $ -153.61M | $ -650.17M | $ 377.66M | $ -348.87M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.90B | $ 1.69B | $ 1.82B | $ 2.38B | $ 1.69B |
| Total Assets | $ 2.24B | $ 2.23B | $ 2.24B | $ 2.75B | $ 1.83B |
| Total Debt | $ 223.69M | $ 238.63M | $ 244.02M | $ 225.03M | $ 61.43M |
| Net Debt | $ -74.56M | $ -150.84M | $ 32.14M | $ -698.00M | $ -1.11B |
| Total Liabilities | $ 309.95M | $ 346.77M | $ 367.58M | $ 352.42M | $ 163.73M |
| Stockholders' Equity | $ 1.93B | $ 1.88B | $ 1.88B | $ 2.40B | $ 1.66B |
| Cash Flow | |||||
| Free Cash Flow | $ -144.68M | $ -269.85M | $ -532.93M | $ 457.27M | $ -256.72M |
| Operating Cash Flow | $ -142.77M | $ -260.38M | $ -495.74M | $ 538.97M | $ -238.37M |
| Investing Cash Flow | $ -280.48M | $ 374.65M | $ -258.65M | $ -1.04B | $ -541.17M |
| Financing Cash Flow | $ 331.98M | $ 62.66M | $ 38.59M | $ 250.94M | $ 1.02B |